<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151358</url>
  </required_header>
  <id_info>
    <org_study_id>MERIT-NHL</org_study_id>
    <nct_id>NCT01151358</nct_id>
  </id_info>
  <brief_title>Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy</brief_title>
  <acronym>MERIT-NHL</acronym>
  <official_title>Multicenter Prospective Evaluation of Patient- and Lesion Specific Prognostic Factors for Standard RadioImmunoTherapy With 90-Yttrium-labeled Anti-CD20 in Follicular Non-Hodgkin´s Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MERIT-NHL as an addendum to the International Registry of Radioimmunotherapy (RIT registry)
      pooling clinical data of patients who suffered from a non-Hodgkin´s lymphoma also includes
      the documentation of the respective FDG-PET and CT-image files in an online archive.

      Based on these documented clinical and imaging data, the MERIT study group centrally performs
      an intra- as well as interindividual evaluation of follicular CD20+ lymphoma lesions before
      and after radioimmunotherapy. According to this, the aim of the MERIT-NHL study is to
      prospectively identify yet unknown patient- and lesion specific prognostic factors predicting
      patient´s outcome in line with the therapeutic modality radioimmunotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of patient- and lesion specific prognostic factors of radioimmunotherapy</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of diagnostical relevance of FDG-PET- and CT-image data findings in staging and re-staging of follicular non-Hodgkin´s lymphoma as well as in documentation of patient´s outcome after standard radioimmunotherapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Follicular Lymphoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who suffer from a relapsed and/or refractory follicular non-Hodgkin´s lymphoma
        (FL) or patients with partial remission after induction chemotherapy of FL
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  standard radioimmunotherapy with 90-yttrium-labeled anti-CD20-antibodies in treatment
             of relapsed and/or refractory follicular NHL or partial remission after induction
             chemotherapy

          -  finding of at least one image-guided measurable lymphoma lesion

          -  existence of FDG-PET- and CT-image data of at most 8 weeks before treatment

          -  signed patient´s agreement for RIT registry and MERIT-NHL

        Exclusion Criteria:

          -  other therapy modalities than standard radioimmunotherapy (e.g. consolidation)

          -  solely CNS-lymphoma or primary effusion lymphoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl-Martin Kirsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaetsklinikum des Saarlandes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aleksandar Grgic, MD</last_name>
    <phone>+49-6841-16-22201</phone>
    <email>merit@uks.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anja Hoock</last_name>
    <phone>+49-6841-16-22201</phone>
    <email>merit@uks.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Nuclear Medicine, Saarland University Hospital</name>
      <address>
        <city>Homburg (Saar)</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandar Grgic, MD</last_name>
      <phone>+49-6841-16-22201</phone>
      <email>merit@uks.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Karlsruhe, Dept. of Nuclear Medicine</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Puskas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Kiel-Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Technical University, Dept. of Nuclear Medicine</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klemens Scheidhauer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>June 25, 2010</last_update_submitted>
  <last_update_submitted_qc>June 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Carl-Martin Kirsch, MD</name_title>
    <organization>University Hospital, Saarland</organization>
  </responsible_party>
  <keyword>radioimmunotherapy</keyword>
  <keyword>follicular non-Hodgkin´s lymphoma</keyword>
  <keyword>FDG-PET</keyword>
  <keyword>prognostic factors</keyword>
  <keyword>multicenter study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

